Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Takecab

Celgene building

Myeloma market set to be $9bn by 2021

New research shows it will pushed by a growing prevalence of the disease

- PMLiVE

J&J buys into Alligator’s immuno-oncology candidate

Will spend $700m on the early-stage cancer deal

Roche Basel Switzerland

Roche and AbbVie’s leukaemia drug set for filing by year-end

Blood cancer treatment venetoclax faces a tough market if approved

- PMLiVE

US filing aims to elevate Brintellix above its competition

Drug looking for an edge in the highly competitive major depressive disorder market

- PMLiVE

Healthcare gets more independence in Google restructuring

New ‘Alphabet’ company will put tech giant’s health ventures centre-stage

- PMLiVE

Shire makes shock $30bn bid for Baxalta

Irish firm seeking to buy the newly spun-out biotech that used to be part of Baxter

- PMLiVE

Humira gains EU licence first for Hidradenitis Suppurativa

Thirteenth licence for the drug in Europe

RRD International hires Ulrich Thienel as CDMO

Company expands leadership team with former Takeda VP

- PMLiVE

FDA approves four new medicines across multiple areas

Sanofi/Regeneron, BMS, AbbVie and Novartis all chalk up major approvals

- PMLiVE

AbbVie and C2N take tau antibody into clinic

Treatment being assessed for a progressive neurodegenerative disorder

- PMLiVE

J&J starts to feel biosimilar competition bite

Secondquarter Remicade sales outside the US dropped 26%

- PMLiVE

Takeda files ‘oral Velcade’ for myeloma in US

Follow up could be the first pill approved for this rare cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links